Most of our travel restrictions and the limitations on the number of visitors to our facilities remain firmly in place.

Oct 30, 2020 / CEO / receipt, needs a key / Stephan Tanda, CEO | earnings call 2020-10-30 | transcript bebae410-0f86-4ec5-8cf0-8a7bee9516fa | chars 2547-2666 | segment 2

We have operating overhead costs that we must absorb while we are reducing some labor, travel, and other costs.

Jul 31, 2020 / CEO / receipt, needs a key / Stephan Tanda, CEO | earnings call 2020-07-31 | transcript 93c43fb1-a8a1-442c-bd78-6b3b5b0f6c9f | chars 6315-6426 | segment 6

As certain economies begin to reopen, we expect the recovery in our beauty, beverage, and prescription pharma business to gradually progress. However, this recovery is likely to occur at the measured pace given the uncertainties around the COVID-19 variant and very limited intercontinental and inter-Asian travel.

Jul 30, 2021 / CEO / receipt, needs a key / Stefan Tanda, CEO | earnings call 2021-07-30 | transcript b622fe1d-6ed6-4589-990f-e7ecb76a95d2 | chars 15912-16226 | segment 16